lncRNAs: potential therapeutic targets and biomarkers for pancreatic cancer?

Expert Opin Ther Targets. 2021 Jul;25(7):521-528. doi: 10.1080/14728222.2021.1938541. Epub 2021 Aug 11.

Authors

Marta Montes¹, Luis Arnes^{1

2}

Affiliations

¹ Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark.
² Biotech Research and Innovation Centre, The Novo Nordisk Foundation Center for Stem Cell Biology, Copenhagen, Denmark.

PMID: 34077329
DOI: 10.1080/14728222.2021.1938541

No abstract available

Keywords: Pancreatic ductal adenocarcinoma; acquired resistance; biomarkers; enhancers; lncRNAs; molecular subtypes; targeted therapy.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers
Biomarkers, Tumor
Carcinoma, Pancreatic Ductal* / genetics
Gene Expression Regulation, Neoplastic
Humans
Pancreatic Neoplasms* / diagnosis
Pancreatic Neoplasms* / genetics
Pancreatic Neoplasms* / therapy
Prognosis
RNA, Long Noncoding* / genetics

Substances

Biomarkers
Biomarkers, Tumor
RNA, Long Noncoding